Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing logic, facts. The shareprices were manipulated down after data release in Nov15 and July16.
I understand you were not around this board at the time.
Eg from SEC 10K December 29th 2015 Limk
We intend to identify and initiate discussions with potential partners in the next 12 months.
From December 29th 2015 PR regarding upcoming milestones:
"Initiate double-blinded, randomized, placebo-controlled Phase 2 human trial of ANAVEX 2-73 in non-disclosed indication."
All we can say that this non-disclosed indication is Rett, but that is it. I guess it depends on how flexible one is with the time concept of "upcoming"
Oh and this was an upcoming milestone too:
"In-licensing to complement current pipeline – ongoing"
Anyone any news?
I said late 2015, early 2016. Listen to the webcasts of those days. No I have exact link in mind but it was widely reported around here.
Again free lunch money.
Soligenix Receives $2.5M in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
Mon August 14, 2017 6:00 AM|PR Newswire|About: SNGX
PRINCETON, N.J., Aug. 14, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised an option to fund GMP (good manufacturing practices) compliant RiVax® bulk drug substance and finished drug product manufacturing, which is required for the conduct of future preclinical and clinical safety and efficacy studies. The overall objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax®, in combination with the company's ricin toxin vaccine, RiVax®, as a medical countermeasure to prevent the effects of ricin exposure.
The exercised option for contract #HHSN272201400039C will provide Soligenix with approximately $2.5M in additional non-dilutive funding, bringing the total amount awarded to date under this contract to $21.2M. If all contract options are exercised, the total award of up to $24.7 million will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax® with the US Food and Drug Administration (FDA).
"The exercise of this option demonstrates the positive and productive collaboration between NIAID and the Soligenix team," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With this recent option exercise by NIAID, along with the one exercised this past June, we now have approximately $4.5M in additional non-dilutive funding that will allow us to proceed with both GMP manufacture and preclinical efficacy studies. We look forward to accelerating this important work with NIAID and engaging the FDA to advance the RiVax® program. We thank the NIAID team for their continued support and contribution to the Soligenix development program."
Thanks for your opinion.
Disagree. Anytime (good) results were released, they have been abused to walk down the share price. Eg November 2015, July 2016. Hopefully this is the reason why there was no July 2017 presence at AAIC.
No Anavex is not partnering with the Australian government. They applied for and received funds to run the current and extended p2a. Nothing known about new trials.
As for MJFF: that was a grant for preclinical work. No further news or grants received at this stage.
Yes he did. Go back to webcast of late 2015 and early 2016.
I do hope you are right and I do not question Misslings honor.
Years end is quite a big cliffhanger, especially regarding the trial initiation of 3 trials, which was just re-affirmed last week.
But there will be no data readout on Rett in 2017 as was initially mentioned in a webcast (as a possibility)
If anything is to happen with BIIB, it will be a collaboration on MS with milestone payment. Perhaps with a non-disclosed addendum on future steps.
Missling stated before he is not in the business of selling the whole shop.
Why is AD not mentioned? I do remember the days when Missling used to say that he will partner for a bigger Alzheimer trial.
Nobody wanted to partner?
Conditions for partnering where not acceptable to Missling?
Who will tell? Missling, but he can't.
Simple: 12 months have gone by since the MTA. Absent any communication, BIIB did not like the results and discarded it.
Please give my any positive evidence to prove the opposite.
There has been zero communication about the MTA since the PR announcing it has been released and the occasional name dropping by Missling in presentations.
Might I also add that BIIB didn't even bother to communicate about this MTA. For any big pharma an MTA is a cheap shot at trying something out for peanuts. The reward is for biotech to reap if big pharma likes it.
So far we know nothing about the results of what happened at BIIB.
Again, I do hope the results are good, but at this stage I see no factual evidence in the public sphere. So far all we have is deductive logical arguments to conclude why retail investors thinks that BIIB liked A2-73 in MS.
Sorry to disagree with you Talon but BIIB was doing the testing. It could be that they did not like it and therefore AVXL continues on its own. If BIIB did like it we will here about it (sooner rather then later I hope).
Yes this is a distinct possibily, and for the record I hope so too as I have money invested in this one.
My main point still is to look at an investment from all perspectices. And way too often people here are counting there eggs before they hatch and see what they wanna see.
Ah they will..
I heard in November 2015 they will be releasing Pk/Pd soon
I heard they will partner for a phase 3 Alzheimer trial
I heard there could be Rett p2 results before end of this year.
Conclusion: between what Missling wants and what reality dictates, there can often be a gap.
Wrong, it says it may lead to another study. It mustn't but it can. A public announcement of this is not required nor is it material.
Really, for me the conclusion is we know nothing factual until an announcement is made. I do not read tealeaves so therefore I go by the knowns.
A collaboration or partnership or anything else is within the reals of possibilities. But at this stage they are nothing else then hopes and whishfull thoughts.
That is a possibility, although I believe a discontinuation by BIIB would never be communicates.
However, as an investor I try to look at it from all angles, not only through rosy glasses.
It is fine for a VP to talk about this.
My observations are twofold:
1) VP's don't announce collaborations or partnerships
2) it is well within the realm of possibilities that BIIB tested A2-73 and discarded it. Let me add for completeness that it is equally possible that they did like the results and have taken it further. We are all just guessing.
I like to keep it realistic rather then all the daydreaming.
Nobody seems to consider the other option: BIIB has explored it and discarded it. No partnership, no money, no PR's.
Possible? Yes.
Probably.
I was just trying to make the point that big strategic decisions never get communicated by vice-presidents.
Every couple of weeks the claims come back that a BIIB partnership will be announced at event X or Y or Z.
But really, we have no clue if it will happen and/or when it will be announced.
VP's do not announce a partnership with a major pharma company.
Period.
Please remind yourself of his stock purchasing plan in June 2015. Peanuts in value but interpreted at the time as a confidince sign that 5-week data was good, and it was.
Lets hope this time it means trial initiation is coming near term.
Why is the trial amendment disappointing?
We will find out sooner if the drug can be administered to a bigger patient population. Should be good news from a revenue perspective.
LOL continued executive turnover and then there is Glynn. Want him out and yet unable to get him booted.
Load of baloney.
Surely after 13 years in this stock these 5% days must be peanuts?
Wondering if that big shareholder will get Glynn booted out. My bet it is all talk and no action.
Bless our benevolent financing company! They mean no financial harm to anyone.
I am Glyn!
Have nothing better to do :)
Hype in yesterday's press release?
Oh boy we do read things differently.
Oh how happy we are with the drip drip share price.
From 6 to 3,5.
Exciting!
Correct, trading on this anemic volume is looking for trouble.
Investment-for-dummies advise
15 months into phase 2 trial???
It is called flexibility and the agility to adapt to changing circumstances. Great that the FDA allows us to target a bigger population.
As for cost, yeah it will cost more. Trial size goes from 80 to 120. Time wise wont make much difference as we will have the interim data analyzes anyway.
Expanding a trial population and trial size is all talk?
Seems these trials qualify as action to me.
Gottlieb has seen this and asked the enlargment? Isn't that a stretch ?
Sounds like a good thing to me If you can enlarge the target population. Also with the PARP mentioning, it is obvious they do this with AZN in the back of their mind.
Eureka! Never thought of it.
Oh TuiTui, you know that this privileged information will not be shared with us. Easier to make claims than provide evidence.